ACE inhibitors for patients with vascular disease without left ventricular dysfunction - May they rest in PEACE?

New England Journal of Medicine

Volumn 351, Issue 20, 2004, Pages 2115-2117

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; INDOLES; TREATMENT FAILURE; VENTRICULAR FUNCTION, LEFT;

EID: 8344222827     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048255     Document Type: Editorial

References (12)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. [Errata, N Engl J Med 2000;342:748, 1376.]
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. [Errata, N Engl J Med 2000;342:748, 1376.]
3. Fox KM. Efficacy on perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
4. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
5. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-65. [Erratum, Circulation 1996;94:1490.]
6. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-65. [Erratum, Circulation 1996;94:1490.]
7. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63.
8. Szmitko P, Wang CH, Weisel RD, Jeffries G, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation. Circulation 2003;108:2041-8.
9. Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 2001;37:1456-60.
10. Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE. Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coron Artery Dis 2004;15:211-7.
11. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
12. Wallentin L, Lagerqvist S, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet 2000;356:9-16.